[
    {
        "pregunta": "1. What is the recommended treatment approach for DMARD-naive patients with moderate-to-high disease activity in rheumatoid arthritis, according to the 2021 American College of Rheumatology guideline?",
        "respuesta": "According to the 2021 American College of Rheumatology guideline, for DMARD-naive patients with moderate-to-high disease activity, methotrexate monotherapy is strongly recommended over hydroxychloroquine, sulfasalazine, or bDMARD/tsDMARD monotherapy.",
        "contexto": [
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR",
            "<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)†|Supplementary Appendix 2|\n|---|---|---|---|\n|Initiation of treatment in DMARD-naive patients with moderate-to-high disease activity| | | |\n|Methotrexate monotherapy is strongly recommended over:| | | |\n|Hydroxychloroquine or sulfasalazine|Very low/low‡|PICO 2a.C1/C2|p. 14–5|\n|bDMARD or tsDMARD monotherapy|Very low/moderate|PICO 5a.C1–4/C5§|p. 61–78|",
            "|Initiation of treatment in DMARD-naive patients with low disease activity| | | |\n|Hydroxychloroquine is conditionally recommended over other csDMARDs.|Very low|PICO 1a.C1–4|p. 1–6|\n|Sulfasalazine is conditionally recommended over methotrexate.|Very low|PICO 1a.C2|p. 2|\n|Methotrexate is conditionally recommended over leflunomide.|Very low|PICO 1a.C3|p. 5|\n|Initiation of treatment in csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#| | | |",
            "| Rheumatoid arthritis should be treated with disease-modifying antirheumatic drugs and follow a treat-to-target management strategy, as detailed in the 2021 ACR Rheumatoid Arthritis Pharmacologic Treatment Guidelines (1). |\n| Individuals with chronic diseases like rheumatoid arthritis seek many available therapies to maintain physical function, reduce pain, and improve their quality of life. |",
            "both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on"
        ]
    },
    {
        "pregunta": "2. In patients with subcutaneous nodules and moderate-to-high disease activity, what is the preferred DMARD therapy based on the guideline?",
        "respuesta": "In patients with subcutaneous nodules and moderate-to-high disease activity in rheumatoid arthritis, the 2021 American College of Rheumatology guideline conditionally recommends methotrexate over alternative DMARDs.",
        "contexto": [
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR",
            "<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)|Supp. App. 2|\n|---|---|---|---|\n|Subcutaneous nodules| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.|Very low|PICO 64|p. 427|",
            "preferences. The voting panel cautioned that many patients treated with certain monoclonal antibodies may require ongoing treatment with methotrexate to prevent the formation of antidrug antibodies Recommendations for specific patient populations (Table 6) Subcutaneous nodules Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-tohigh disease activity Switching to a non-methotrexate DMARD is conditionally recommended over",
            "|Switching to a non-methotrexate DMARD is conditionally recommended over continuation of methotrexate for patients taking methotrexate with progressive subcutaneous nodules.|Very low|PICO 65|p. 428|\n|Pulmonary disease| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease who have moderate-to-high disease activity.|Very low|PICO 67|p. 430|",
            "there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or"
        ]
    },
    {
        "pregunta": "3. For patients with pulmonary disease and moderate-to-high disease activity, what is the recommended DMARD treatment according to the guideline?",
        "respuesta": "The provided information does not specify recommendations for DMARD treatment in patients with pulmonary disease and moderate-to-high disease activity according to the 2021 American College of Rheumatology guideline. Therefore, I am unable to provide a reliable response to this question based on the given data.",
        "contexto": [
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR",
            "there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or",
            "for patients who are candidates for, or are currently receiving checkpoint inhibitor therapy. We anticipate that additional recommendations for patients with systemic rheumatic diseases and solid malignancies will be developed as further data become available. There were vigorous discussions pertaining to recommendations for specific DMARDs in patients with moderate-tohigh disease activity despite csDMARDs and with a history of serious infection. However, the evidence was insufficient to",
            "both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on",
            "<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)†|Supplementary Appendix 2|\n|---|---|---|---|\n|Initiation of treatment in DMARD-naive patients with moderate-to-high disease activity| | | |\n|Methotrexate monotherapy is strongly recommended over:| | | |\n|Hydroxychloroquine or sulfasalazine|Very low/low‡|PICO 2a.C1/C2|p. 14–5|\n|bDMARD or tsDMARD monotherapy|Very low/moderate|PICO 5a.C1–4/C5§|p. 61–78|"
        ]
    },
    {
        "pregunta": "4. What is the suggested course of action for patients with heart failure and inadequate response to csDMARDs, as per the guideline?",
        "respuesta": "For patients with heart failure (specifically NYHA class III or IV) and an inadequate response to conventional synthetic DMARDs, the 2021 American College of Rheumatology guideline conditionally recommends adding a non-TNF inhibitor bDMARD or a tsDMARD over adding a TNF inhibitor.",
        "contexto": [
            "recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy",
            "or IV heart failure and an inadequate response to csDMARDs Switching to a non-TNF inhibitor bDMARD or tsDMARD is conditionally recommended over continuation of a TNF inhibitor for patients taking a TNF inhibitor who develop heart failure These recommendations are based on the risk of worsening heart failure observed in randomized clinical trials of TNF inhibitors in patients with NYHA class III or IV heart failure without RA Lymphoproliferative disorder Rituximab is conditionally recommended",
            "|There is no preferred agent.| | | |\n|IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of conventional synthetic DMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids.|Very low|PICO 23. In patients with systemic JIA without MAS who do not respond to initial therapy with nonbiologic treatments (NSAIDs, glucocorticoids, DMARDs), should nonbiologic treatments be combined or biologic treatment started?|72–130|",
            "|Heart failure| | | |\n|Addition of a non–TNF inhibitor bDMARD or tsDMARD is conditionally recommended over addition of a TNF inhibitor for patients with NYHA class III or IV heart failure and an inadequate response to csDMARDs.|Very low|PICO 70|p. 435|\n|Switching to a non–TNF inhibitor bDMARD or tsDMARD is conditionally recommended over continuation of a TNF inhibitor for patients taking a TNF inhibitor who develop heart failure.|Very low|PICO 71|p. 436|\n|Lymphoproliferative disorder| | | |",
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR"
        ]
    },
    {
        "pregunta": "5. In patients with lymphoproliferative disorder and moderate-to-high disease activity, what is the preferred DMARD therapy based on the guideline?",
        "respuesta": "According to the information provided from the 2021 American College of Rheumatology guideline, for patients with a lymphoproliferative disorder and moderate-to-high disease activity in rheumatoid arthritis, rituximab is conditionally recommended over other DMARDs, as rituximab would not be expected to increase the risk of recurrence or worsening of these lymphoproliferative disorders.",
        "contexto": [
            "RA Lymphoproliferative disorder Rituximab is conditionally recommended over other DMARDs for patients who have a previous lymphoproliferative disorder for which rituximab is an approved treatment and who have moderate-to-high disease activity Rituximab is preferred over other DMARDs, regardless of previous DMARD experience, because it would not be expected to increase the risk of recurrence or worsening of these lymphoproliferative disorders. The recommendation is conditional because of the",
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR",
            "there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or",
            "for patients who are candidates for, or are currently receiving checkpoint inhibitor therapy. We anticipate that additional recommendations for patients with systemic rheumatic diseases and solid malignancies will be developed as further data become available. There were vigorous discussions pertaining to recommendations for specific DMARDs in patients with moderate-tohigh disease activity despite csDMARDs and with a history of serious infection. However, the evidence was insufficient to"
        ]
    },
    {
        "pregunta": "6. How should healthcare providers manage patients with hepatitis B infection initiating rituximab therapy, as per the guideline?",
        "respuesta": "According to the provided information from the 2021 American College of Rheumatology guideline, for patients with hepatitis B core antibody positivity, regardless of hepatitis B surface antigen status, who are initiating rituximab therapy, prophylactic antiviral therapy is strongly recommended over frequent monitoring alone.",
        "contexto": [
            "|Hepatitis B infection| | | |\n|Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating rituximab who are hepatitis B core antibody positive (regardless of hepatitis B surface antigen status).|Very low|PICO 82|p. 459|",
            "disorders. The recommendation is conditional because of the very low-certainty evidence supporting this PICO question. Hepatitis B infection Prophylactic antiviral therapy is strongly recommended over frequent monitoring of viral load and liver enzymes alone for patients initiating rituximab who are hepatitis B core antibody positive (regardless of hepatitis B surface antigen status) Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating",
            "antigen negative These recommendations were made based on the risk of hepatitis B reactivation due to core antibody and surface antigen status and the specific DMARD being initiated and are consistent with the updated American Association for the Study of Liver Diseases guidance Persistent hypogammaglobulinemia without infection In the setting of persistent hypogammaglobulinemia without infection, continuation of rituximab therapy for patients at target is conditionally recommended over",
            "|Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating any bDMARD or tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen positive.|Very low|PICO 83|p. 464|",
            "recommended over frequent monitoring alone for patients initiating any bDMARD or tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen positive Frequent monitoring alone of viral load and liver enzymes is conditionally recommended over prophylactic antiviral therapy for patients initiating a bDMARD other than rituximab or a tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen negative These recommendations were made based on the risk of"
        ]
    },
    {
        "pregunta": "7. What is the recommended approach for DMARD-naive patients with nonalcoholic fatty liver disease and moderate-to-high disease activity, according to the guideline?",
        "respuesta": "According to the 2021 American College of Rheumatology guideline, methotrexate is conditionally recommended over alternative DMARDs for DMARD-naive patients with nonalcoholic fatty liver disease, provided they have normal liver enzymes and liver function tests, and no evidence of advanced liver fibrosis, who have moderate-to-high disease activity.",
        "contexto": [
            "|Nonalcoholic fatty liver disease| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for DMARD-naive patients with nonalcoholic fatty liver disease, normal liver enzymes and liver function tests, and no evidence of advanced liver fibrosis who have moderate-to-high disease activity.|Very low|PICO 87|p. 489|\n|Persistent hypogammaglobulinemia without infection| | | |",
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR",
            "both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on",
            "|Frequent monitoring alone is conditionally recommended over prophylactic antiviral therapy for patients initiating a bDMARD other than rituximab or a tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen negative.|Very low|PICO 84|p. 471|\n|Nonalcoholic fatty liver disease| | | |",
            "<ul>\n<li>DMARDs = biologic disease-modifying antirheumatic drugs; RA = rheumatoid arthritis; TTT = treat-to- target; bDMARD = biologic DMARD; tsDMARD = targeted synthetic DMARD; NAFLD = nonalcoholic fatty liver disease.</li>\n</ul>"
        ]
    },
    {
        "pregunta": "8. In patients with persistent hypogammaglobulinemia without infection, what is the guideline's recommendation regarding rituximab therapy continuation?",
        "respuesta": "According to the information provided from the 2021 American College of Rheumatology guideline, in the setting of persistent hypogammaglobulinemia without infection, the continuation of rituximab therapy for patients who are at target is conditionally recommended over switching to a different bDMARD or tsDMARD.",
        "contexto": [
            "|Persistent hypogammaglobulinemia without infection| | | |\n|In the setting of persistent hypogammaglobulinemia without infection, continuation of rituximab therapy for patients at target is conditionally recommended over switching to a different bDMARD or tsDMARD.|Very low|PICO 66|p. 429|\n|Previous serious infection| | | |",
            "antigen negative These recommendations were made based on the risk of hepatitis B reactivation due to core antibody and surface antigen status and the specific DMARD being initiated and are consistent with the updated American Association for the Study of Liver Diseases guidance Persistent hypogammaglobulinemia without infection In the setting of persistent hypogammaglobulinemia without infection, continuation of rituximab therapy for patients at target is conditionally recommended over",
            "|Recommendation: For patients with GPA/MPA receiving remission maintenance therapy with rituximab who have hypogammaglobulinemia (e.g., IgG &lt;3 gm/liter) and recurrent severe infections, we conditionally recommend immunoglobulin supplementation.|44|Very low|\n|Ungraded position statement: The duration of non-GC remission maintenance therapy in GPA/MPA should be guided by the patient’s clinical condition, preferences, and values.|26|Low to moderate|",
            "rituximab therapy for patients at target is conditionally recommended over switching to a different bDMARD or tsDMARD Continuing rituximab in patients who are at target is preferred because of the uncertain clinical significance of hypogammaglobulinemia in patients without infection. Although an increased risk of infection has been described in RA patients with hypogammaglobulinemia, it is not known if a switch in DMARDs in patients who are at target is more effective in lowering infection risk",
            "in patients who are at target is more effective in lowering infection risk while maintaining disease control than continuation of rituximab. The recommendation is conditional because physician and patient risk tolerance is likely to vary depending on the degree of hypogammaglobulinemia and patient-specific risk factors for infection. Previous serious infection Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within the"
        ]
    },
    {
        "pregunta": "9. For patients with a history of serious infection within the previous 12 months and moderate-to-high disease activity, what is the recommended treatment approach according to the guideline?",
        "respuesta": "According to the 2021 American College of Rheumatology guideline, for patients with a history of serious infection within the previous 12 months and moderate-to-high disease activity despite csDMARD monotherapy, the addition of csDMARDs is conditionally recommended over the addition of a bDMARD or tsDMARD.",
        "contexto": [
            "a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend",
            "|Previous serious infection| | | |\n|Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity despite csDMARD monotherapy.|Very low|PICO 88|p. 490|",
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR",
            "2022 American College of Rheumatology (ACR) Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases      D064A5AD64D848FEC553AA8136BD6112 10.1002/acr.25045  Conclusion: Application of these recommendations should take into consideration patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings.",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>"
        ]
    },
    {
        "pregunta": "10. How should healthcare providers manage patients with nontuberculous mycobacterial lung disease and moderate-to-high disease activity despite csDMARD monotherapy, based on the guideline's recommendations?",
        "respuesta": "According to the 2021 American College of Rheumatology guideline, for patients with nontuberculous mycobacterial lung disease and moderate-to-high disease activity despite csDMARD monotherapy, it is conditionally recommended to add csDMARDs over adding a bDMARD or tsDMARD. Additionally, abatacept is conditionally recommended over other bDMARDs and tsDMARDs for these patients.",
        "contexto": [
            "|Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with nontuberculous mycobacterial lung disease who have moderate-to-high disease activity despite csDMARD monotherapy.|Very low|PICO 92|p. 498|\n|Abatacept is conditionally recommended over other bDMARDs and tsDMARDs for patients with nontuberculous mycobacterial lung disease who have moderate-to-high disease activity despite csDMARDs.|Very low|PICO 93|p. 499|</p>",
            "over other bDMARDs and tsDMARDs for patients with NTM lung disease who have moderate-tohigh disease activity despite csDMARDs Abatacept is conditionally recommended over other bD MARDs and tsDMARDs based on population data extrapolated from studies on tuberculosis The preceding 3 recommendations are conditional because of the very low-certainty evidence supporting the analysis of the differences in treatment outcomes posed by these PICO questions. DISCUSSION The ACR guidelines were developed to",
            "in patients receiving either inhaled or oral glucocorticoids Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with NTM lung disease who have moderate-to-high disease activity despite csDMARD monotherapy This recommendation is based on the lower expected risk of NTM lung disease associated with csDMARDs compared to bDMARDs and tsDMARDs Abatacept is conditionally recommended over other bDMARDs and tsDMARDs for patients with NTM lung disease who",
            "|Addition of/switching to DMARDs is conditionally recommended over initiation/dose escalation of glucocorticoids for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity.|Very low|PICO 90 and PICO 91|p. 496–7|\n|Nontuberculous mycobacterial lung disease| | | |",
            "treatment of RA in patients with NTM lung disease. Areas covered in the 2015 guidelines that are not covered in this update include recommendations for patients with hepatitis C and solid malignancies. The panel did not vote on specific recommendations for patients with hepatitis C because curative antiviral therapy is now widely available. The panel did deliberate over PICO questions related to use of DMARDs in patients with solid malignancies. However, given the changing landscape of"
        ]
    }
]